Does porcine circovirus type 3 (PCV3) interfere with porcine circovirus type 2 (PCV2) vaccine efficacy?

2019 ◽  
Author(s):  
Aleksandra Woźniak ◽  
Dagmara Miłek ◽  
Piotr Bąska ◽  
Tomasz Stadejek
Keyword(s):  
Vaccine Efficacy ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Pcv2 Vaccine ◽  
Type 3

scholarly journals Porcine Reproductive and Respiratory Syndrome Virus Infection at the Time of Porcine Circovirus Type 2 Vaccination Has No Impact on Vaccine Efficacy

2010 ◽  
Vol 17 (12) ◽  
pp. 1940-1945 ◽  
Author(s):  
A. Sinha ◽  
H. G. Shen ◽  
S. Schalk ◽  
N. M. Beach ◽  
Y. W. Huang ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Respiratory Syndrome Virus ◽  
Lymphoid Tissues ◽  
Pcv2 Vaccine ◽  
Pcv2 Vaccination ◽  
The Impact

ABSTRACT Several porcine circovirus type 2 (PCV2) vaccines are now commercially available and have been shown to be effective at decreasing the occurrence of porcine circovirus-associated disease (PCVAD). Many herds are coinfected with PCV2 and porcine reproductive and respiratory syndrome virus (PRRSV). Some producers and veterinarians are concerned that if pigs are vaccinated for PCV2 at or near the time that they are typically infected with PRRSV, the efficacy of the PCV2 vaccine will be compromised. The impact of PRRSV on PCV2 vaccination is unclear and has not been investigated under controlled conditions. The objective of the present study was to determine whether the presence of PRRSV viremia has an effect on the efficacy of commercial PCV2 vaccinations. Three-week-old PCV2-negative conventional pigs with passively derived anti-PCV2 antibodies were either vaccinated with one of three commercial PCV2 vaccines or left nonvaccinated. A portion of the pigs were infected with PRRSV 1 week prior to PCV2 vaccination. To determine vaccine efficacy, a PCV2 challenge was conducted at 8 weeks of age. PCV2 vaccination, regardless of PRRSV infection status at the time of vaccination, was similarly effective in inducing an anti-PCV2 IgG response in the presence of maternally derived immunity and in protecting the pigs from PCV2 challenge, as determined by a reduction in the level of PCV2 viremia and a reduction in the prevalence and amount of PCV2 antigen in lymphoid tissues in vaccinated pigs compared to nonvaccinated pigs. The results indicate that acute PRRSV infection at the time of PCV2 vaccination has no adverse effect on PCV2 vaccine efficacy.

scholarly journals Effects of an Inactivated Porcine Circovirus Type 2 (PCV2) Vaccine on PCV2 Virus Shedding in Semen from Experimentally Infected Boars

2011 ◽  
Vol 18 (7) ◽  
pp. 1091-1096 ◽  
Author(s):  
Hwi Won Seo ◽  
Kiwon Han ◽  
Duyeol Kim ◽  
Yeonsu Oh ◽  
Ikjae Kang ◽  
...  
Keyword(s):  
Immunological Response ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Virus Shedding ◽  
Pcv2 Vaccine ◽  
Group 3 ◽  
Group 2 ◽  
Negative Controls

ABSTRACTThe objective of the present study was to determine the effect of an inactivated porcine circovirus type 2 (PCV2) vaccine on PCV2b virus shedding in the semen of experimentally infected boars by measuring the immunological response and the PCV2b DNA load in blood and semen. Twelve boars were randomly divided into three groups. The boars in group 1 (n= 4) were immunized with an inactivated PCV2 vaccine and were challenged with PCV2b. The boars in group 2 (n= 4) were only challenged with PCV2b. The boars in group 3 (n= 4) served as negative controls. The number of PCV2 genome copies of PCV2 in the serum and semen were significantly lower in vaccinated challenged boars than in nonvaccinated challenged boars at 7, 10, 14, 21, 32, 35, 42, 49, and 60 days postinoculation. The number of PCV2b genomes in the semen correlated with the number of PCV2b genomes in the blood in both vaccinated challenged (R= 0.714) and nonvaccinated challenged (R= 0.861) boars. The results of the present study demonstrate that the inactivated PCV2 vaccine significantly decreases the amount of PCV2b DNA shedding in semen from vaccinated boars after experimental infection with PCV2b.

scholarly journals Identification of porcine circovirus type 2 (PCV2), type 3 (PCV3) and porcine parvovirus (PPV) in swine by multiplex PCR test

2021 ◽  
Vol 20 (03) ◽  
pp. 11-17
Author(s):  
Phat X. Dinh
Keyword(s):  
Multiplex Pcr ◽  
Real Time ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Serum Samples ◽  
Single Target ◽  
Ns1 Gene ◽  
Type 3

This study aimed to simultaneously detect three important viruses reported to be involved in the reproductive problems of sows. A multiplex PCR (mPCR) test was developed to provide rapid diagnosis of porcine circovirus type 2 and 3 (PCV2, PCV3) and to illustrate parvovirus (PPV) prevalence in sow herds. Three pairs of specific primers were designed to target PCV2 Cap gene, PCV3 Cap gene and PPV NS1 gene, with predicted mPCR products of 702 bp, 267 bp and 380 bp, respectively. The detection limit of mPCR was 100 copies/reaction per target gene. The mPCR was run against a panel of 94 swine serum samples whose infection status had been pre-determined by commercial real-time PCR kits. Sequencing of mPCR products performed with clinical serum samples accurately confirmed the results. Overall, the results indicated that the mPCR functioned accurately and specifically and matched 100% with the single-target real-time PCRs. The mPCR was developed successfully and can be used in routine diagnosis of PCV2, PCV3 and PPV.

Prevalence and genetic analysis of porcine circovirus type 2 (PCV2) and type 3 (PCV3) between 2018 and 2020 in central China

2021 ◽  
pp. 105016
Author(s):  
Tong Xu ◽  
Yuan-Hang Zhang ◽  
Run-bo Tian ◽  
Cheng-Yao Hou ◽  
Xin-Sheng Li ◽  
...  
Keyword(s):  
Genetic Analysis ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Central China ◽  
Porcine Circovirus ◽  
Type 3

CHARACTERIZATION OF PORCINE PARVOVIRUS TYPE 3 AND PORCINE CIRCOVIRUS TYPE 2 IN WILD BOARS (SUS SCROFA) IN SLOVAKIA

2015 ◽  
Vol 51 (3) ◽  
pp. 703-711 ◽  
Author(s):  
Ivan Sliz ◽  
Michaela Vlasakova ◽  
Anna Jackova ◽  
Stefan Vilcek
Keyword(s):  
Sus Scrofa ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Porcine Parvovirus ◽  
Wild Boars ◽  
Type 3

scholarly journals DETECTION OF PORCINE CIRCOVIRUS TYPE 3 IN RUSSIAN PIG HOLDINGS

2019 ◽  
pp. 29-33
Author(s):  
M. V. Biryuchenkova ◽  
A. M. Timina ◽  
A. V. Shcherbakov
Keyword(s):  
Russian Federation ◽  
Clinical Manifestations ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Economic Losses ◽  
Unknown Etiology ◽  
The Russian Federation ◽  
Type 3

Diseases associated with porcine circoviruses (mainly with porcine circovirus type 2) have various manifestations, are common in pigs in countries having well-developed pig industry and responsible for significant economic losses. Porcine circovirus type 3 (PCV-3) causing systemic inflammation of unknown etiology in animals was detected the USA in 2015. Later, data on PCV-3 detection in Asia, Europe and South America were published. Analysis of literature data on current epidemic situation on PCV-3 infection in foreign countries as well as the disease clinical manifestations and postmortem lesions are described. Results of molecular and genetic tests of biomaterials collected from pigs in 51 holdings located in 28 regions of the Russian Federation are presented. A total of 280 samples of biological materials of different types (organs, tissues, stillborn piglets) collected from domestic pigs with respiratory, reproductive and neurological disorders, dermatitis and from emaciated pigs were tested and PCV-3 genome was detected in 11 samples from 9 holdings located in 5 regions of the Russian Federation. Porcine circovirus type 3 was detected in lung, bronchial and mediastinal lymph node, spleen tissues from grower and fattening piglets, adult pigs and aborted fetuses. Samples that were positive for PCV-3 DNA when tested with molecular methods (PCR, real-time PCR) were tested for other pathogens. The following pathogens were also detected in 6 out of 11 samples (55%): Actinobacillus pleuropneumoniae, Mycoplasma hyorhinis, Streptococcus suis, Haemophilus parasuis, Mycoplasma hyopneumoniae and Pasteurella multocida. Porcine circovirus type 2 was detected in one sample. Presented test results are indicative of probable combined etiology of respiratory and reproductive disorders in tested pigs that results in various clinical manifestations. Grower and fattening piglets were found to be the most susceptible to PCV-3-associated disease. Further studies are required for identification of actual PCV-3 pathogenicity and its prevalence in the territory of the Russian Federation.

Enhanced immune response to inactivated porcine circovirus type 2 (PCV2) vaccine by conjugation of chitosan oligosaccharides

2017 ◽  
Vol 166 ◽  
pp. 64-72 ◽  
Author(s):  
Guiqiang Zhang ◽  
Peiyuan Jia ◽  
Gong Cheng ◽  
Siming Jiao ◽  
Lishi Ren ◽  
...  
Keyword(s):  
Immune Response ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Chitosan Oligosaccharides ◽  
Pcv2 Vaccine

scholarly journals A Live-Attenuated Chimeric Porcine Circovirus Type 2 (PCV2) Vaccine Is Transmitted to Contact Pigs but Is Not Upregulated by Concurrent Infection with Porcine Parvovirus (PPV) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and Is Efficacious in a PCV2b-PRRSV-PPV Challenge Model

2011 ◽  
Vol 18 (8) ◽  
pp. 1261-1268 ◽  
Author(s):  
T. Opriessnig ◽  
H. G. Shen ◽  
N. Pal ◽  
S. Ramamoorthy ◽  
Y. W. Huang ◽  
...  
Keyword(s):  
Protective Immunity ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Respiratory Syndrome Virus ◽  
Porcine Parvovirus ◽  
Concurrent Infection ◽  
Pcv2 Vaccine

ABSTRACTThe live chimeric porcine circovirus type 2 (PCV2) vaccine with the capsid gene of the emerging subtype 2b cloned in the genomic backbone of the nonpathogenic PCV1 is attenuatedin vivoand induces protective immunity against PCV2. To further determine the safety and efficacy of this experimental vaccine, we tested for evidence of pig-to-pig transmission by commingling nonvaccinated and vaccinated pigs, determined potential upregulation by simultaneous vaccination and infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV), and determined vaccine efficacy by challenging pigs 4 weeks after vaccination with PCV2b, PRRSV, and PPV. Forty-six 21-day-old, PCV2-naïve pigs were randomly assigned to one of six groups. Twenty-nine of 46 pigs were challenged with PCV2b, PRRSV, and PPV at day 28, 8/46 remained nonvaccinated and nonchallenged and served as negative controls, and 9/46 remained nonchallenged and served as vaccination controls. All animals were necropsied at day 49. PCV1-PCV2 viremia was detected in nonvaccinated contact pigs commingled with vaccinated pigs, indicating pig-to-pig transmission; however, PCV1-PCV2 DNA levels remained low in all vaccinated and contact pigs regardless of concurrent infection. Finally, vaccination 28 days before challenge resulted in significantly (P< 0.05) decreased amounts of PCV2 in tissues and sera and significantly (P< 0.05) reduced macroscopic and microscopic lesions. The results of this study indicate that the experimental live-attenuated chimeric PCV2 vaccine, although transmissible to contact pigs, remains attenuated in pigs concurrently infected with PRRSV and PPV and induces protective immunity against PCV2b when it is administered 28 days before PCV2 exposure.

Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination

2010 ◽  
Vol 142 (3-4) ◽  
pp. 177-183 ◽  
Author(s):  
Tanja Opriessnig ◽  
Abby R. Patterson ◽  
Darin M. Madson ◽  
Narinder Pal ◽  
Sheela Ramamoorthy ◽  
...  
Keyword(s):  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Pcv2 Vaccine ◽  
Induced Immunity
Sign in / Sign up

Export Citation Format

Share Document